Buy or sell Exicure stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Exicure Stock

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

About Exicure Stock

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Funding History

December 2009$2.5M
December 2011$5.4M
July 2013$0
June 2014$13.6M
February 2015$4.5M
October 2015$14.8M
January 2016$0
September 2017$20.0M

Management

COO

David A. Giljohann

CTO

Sergei Gryaznov

Founder

Chad A. Mirkin

Founder

C. Shad Thaxton

Director Program Management

Weston Daniel

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Exicure or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo